MYWOT
Child safety
Confidence
Trustworthiness
Confidence
MALICIOUS CONTENT INDICATORS
Eyewiretoday.com most likely does not offer any malicious content.
Secure connection support
HTTPS
Eyewiretoday.com provides SSL-encrypted connection.
ADULT CONTENT INDICATORS
Eyewiretoday.com most likely does not offer any adult content.
Audience
-
Gender
Men
18.5%
Women
96%
Popular pages
-
Eyewire+
Get breaking ophthalmic news, device and drug updates, clinical trial coverage, thought-leader perspective, and industry announcements.
-
Eyewire+
Ophthalmologists share cases in which this measurement influenced their treatment plans. Carol L. Shields, MD, and Jonathan F. Russell, MD, PhD Retina Today About Eyewire+ Eyewire+ keeps readers upda...
-
Eyewire Today | Avedro Receives Long-Awaited FDA Approval for its Cross-Linking Platform for
Avedro has received approval from the FDA for its corneal collagen cross-linking platform, the KXL System, along with two photoenhancers -- Photrexa Viscous and Photrexa -- indicatied fo…
-
Eyewire Today | EyewireTV — Ziemer Z6 Bladeless Cataract Module, New Zeiss OR Management System, ORA
In this week’s EyewireTV, Alcon enters into a strategic alliance with PowerVision in which Alcon will provide funding for the clinical development of PowerVision's fluid-based IOL technology; and Vale...
-
Eyewire Today | pSivida's Medidur Meets Primary Efficacy Endpoint in Phase 3 Trial of Posterior
pSivida announced positive topline results from its first phase 3 clinical trial evaluating the safety and efficacy of Medidur for the treatment of chronic noninfectious uveitis affecting the posterio...
-
Eyewire Today | International Study Shows 3-Year Benefits of Glaukos iStent Trabecular Micro-Bypass
Glaukos announced that a new international clinical study, published in the Journal of Cataract and Refractive Surgery, showed use of the iStent Trabecular Micro-Bypass Stent in conjunction with catar...